jRCT2033230587招募中不适用
A Phase III Study Evaluating the Efficacy and Safety of CLS2901C in Patients with Osteoarthritis of the Knee
试验速览
- 阶段
- 不适用
- 状态
- 招募中
- 入组人数
- 96
- 主要终点
- -
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized Controlled Trial
- 干预模型
- Parallel Assignment
- 主要目的
- Treatment Purpose
- 盲法
- Single Blind
入排标准
- 年龄范围
- 20age old over 至 80age old not（—）
- 性别
- All
入选标准
- •Male or female aged 20 to 79 years at informed consent. 2) Diagnosis of OAK classified as Kellgren-Lawrence (K-L) Grade 2 to 4 based on plain lower extremity X-ray. 3) OAK eligible for proximal tibial osteotomy based on the following criteria: Range of motion (ROM): >=120 degree flexion, <=5 degree extension 4) Preoperative cartilage defect of the femoral condyle/trochlear groove or medial tibial condyle with an area of >=4 cm2 per defect site. 5) Total defect area of <=21 cm2 in individuals with multiple cartilage defects. 6) Body mass index (BMI) <
- •No coexisting ligament injury requiring surgery, and no meniscal injury requiring suturing or surgical repair other than partial resection, in the target knee. 8) No history of ligament reconstruction, meniscal suturing, total meniscectomy or bone marrow stimulation, and no history of treatment with regenerative medicine products (including investigational products), cell processing products or gene therapy, in the target knee. 9) No history of treatment with hyaluronic acid products and/or opioid for severe pain in the target knee within 1 month prior to informed consent. 10) No history of treatment with corticosteroid products and/or immunosuppressive drug in the target knee within 3 months prior to informed consent. 11) No history of platelet-rich plasma (PRP) therapy within 6 months prior to informed consent. 12) Non-smoker; provided, however, that smokers will be eligible for study entry if they consent to abstain from smoking from 3 months prior to proximal tibial osteotomy or proximal tibial osteotomy+RMSC until postoperative bone healing. 13) Written informed consent to participate in the study on a voluntary basis.
排除标准
- •Requires surgical treatment of the non-target knee during the study period. 2) Any coexisting illness that would interfere with surgery under general anesthesia or that would affect knee surgery. 3) Systemic inflammatory disease such as rheumatoid arthritis. 4) Active infectious disease such as bacterial, fungal or viral infection. 5) Positive serology assay result (HBs antigen, HBc antibody/HBs antibody, HCV antibody, HIV-1/2 antibody, HTLV-1 antibody, Treponema pallidum antibody) or positive nucleic acid amplification assay result (HBV-DNA, HCV-RNA, HIV-RNA). However, patients who return a positive assay result for HBs antibody and negative assay result for HBV-DNA due to inoculation with hepatitis B vaccine will still be eligible for study entry. 6) Serious disease such as liver disorder, renal disorder, heart disease, lung disease, blood disease or metabolic disease that would make the patient unsuitable for study entry in the opinion of the investigator. 7) Diagnosed or suspected malignant tumor or history of malignant tumor within the past 5 years. 8) Uncontrolled psychiatric disorder. 9) Poorly-controlled diabetes (HbA1c: >7.0%). 10) Previous history of septic arthritis of the target knee. 11) Women who are pregnant or breastfeeding, or women of childbearing potential. Women of childbearing potential must agree to use the following contraceptive methods (i.e., contraceptives and medical devices that are approved/certified in Japan) or to abstain completely from sexual intercourse from the time of informed consent and for the study duration (excluding the follow-up period) in order to be eligible for study entry. (a) Primary contraceptive methods: Oral contraceptives, intrauterine devices (IUDs) including progesterone-releasing systems. (b) Adjunctive contraceptive methods: Condoms Use of a primary contraceptive method is mandatory, whereas use of the adjunctive contraceptive method must be in conjunction with a primary contraceptive method. Given that oral contraceptive doses can be missed and that their effects may be diminished when used concomitantly with other medications or dietary health supplements, subjects should consider changing their primary contraceptive method. 12) Participated in another clinical study within the past 6 months, currently participating in another clinical study, or planning to participate in another clinical study while also participating in the present study. 13) Known history of hypersensitivity to antibiotics (benzylpenicillin potassium, streptomycin sulfate, amphotericin B). 14) Known history of hypersensitivity to bovine-derived materials. 15) Any other reason the investigator deems the subject unsuitable for study entry.
结局指标
主要结局
-
Absolute change from baseline KOOS4 score at postoperative Week 52
次要结局
- Absolute change from preoperative KOOS5 score and each KOOS subscore(postoperative Week 52)
- Lysholm Knee Score (LKS)
- Lower extremity X-ray
- Arthroscopy
- Magnetic Resonance Observation of Cartilage Repair Tissue 2.0 (MOCART 2.0) score(postoperative Week 52)
- Pathology
- Incidence proportion of adverse events (AEs) and defects
研究者
相似试验
未知
2 期
ONO-2745 Phase II StudyPatients undergoing a surgery under general anesthesia requiring opiate analgesticsJPRN-jRCT2080221456ONO PHARMACEUTICAL CO.,LTD.90
已完成
1 期
Phase1 Clinical Trial of OTS102 in Subjects with Solid TumorsSolid tumorJPRN-UMIN000008336OncoTherapy Science, Inc.18
撤回
2 期
The safety and efficacy of STC3141 in patient with COVID-19 Acute Respiratory Distress SyndromeCOVID-19 infectionInfection - Other infectious diseasesRespiratory - Other respiratory disorders / diseasesACTRN12620000588998Grand Medical Pty Ltd160
已完成
1 期
Phase1 Clinical Trial of OTS11101 in Subjects with Solid TumorsSolid TumorsJPRN-UMIN000002700Oncotherapy science,Inc.18
进行中（未招募）
1 期
A study in patients with metastatic breast cancer who have not responded to previous treatment.Breast cancerEUCTR2013-005548-27-ESilly S.A128